Alterity Therapeutics (ATHE) Short term Debt (2015)
Alterity Therapeutics' quarterly Short term Debt came in at $424.62 in Q4 2015, up 4451.55% quarter-over-quarter from $9.33 in Q2 2015.
Alterity Therapeutics has reported Short term Debt for 1 years, with the latest figure at $424.62 in Q4 2015.
- For the quarter ending Q4 2015, Short term Debt changed N/A year-over-year to $424.62; the trailing twelve-month figure through Dec 2015 stood at $424.62 (changed N/A YoY), and the FY2015 full-year result was $9.33, changed N/A from the prior year.
- Short term Debt for Q4 2015 stood at $424.62, up from $9.33 in the prior quarter.
- The five-year high for Short term Debt was $424.62 in Q4 2015, with the low at $9.33 in Q2 2015.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 424.62 |
| Jun 30, 2015 | 9.33 |